ReviewHeliyon2024
From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis.BMC gastroenterology · 2025Pooled it
- The association between organophosphate pesticide residue exposure and non-alcoholic fatty liver disease: A systematic review.Toxicology reports · 2026Review
- Article
- Plant-derived extracellular vesicles as tools and targets for inflammatory diseases.Journal of nanobiotechnology · 2026Review
- Nanoformulations of essential oils for the treatment of fungal diseases, with a focus on dermatophytes.Archives of microbiology · 2026Review
- Article
- Orphan drug uttroside B impedes MASH progression and HCC development in experimental models.JHEP reports : innovation in hepatology · 2026Article
- Targeting metabolic dysfunction-associated steatotic liver disease with phytosomal silymarin and piperine: A natural alternative to fenofibrate in a rat model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Valorisation of citrus peels: implications for cardiovascular diseases and diabetes management.Inflammopharmacology · 2026Review
- Metabolomics for searching non-invasive biomarkers of metabolic dysfunction-associated steatotic liver disease in youth with vertical HIV.Communications medicine · 2025Article
- Non-linear association between metabolic score for insulin resistance and nonalcoholic fatty liver disease: analysis of US National health and nutrition examination survey data, 2017-2020.BMC endocrine disorders · 2025Article
- The Burden of Nonmalignant Metabolic Dysfunction-Associated Steatotic Liver Disease in the Western Pacific Region: A Systematic Analysis From 1990 to 2021.Food science & nutrition · 2025Article
- Induction of Fructose Mediated De Novo Lipogenesis Coexists with the Upregulation of Mitochondrial Oxidative Function in Mice Livers.The Journal of nutrition · 2025Article
- Identification of pyroptosis-associated gene to predict fibrosis and reveal immune characterization in non-alcoholic fatty liver disease.Scientific reports · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease Induced by Microplastics: An Endpoint in the Liver-Eye Axis.International journal of molecular sciences · 2025Review
- Clinical Insights into Non-Alcoholic Fatty Liver Disease and the Therapeutic Potential of Flavonoids: An Update.Nutrients · 2025Review
- Induced pluripotent stem cell-derived mesenchymal stem cells for modeling and treating metabolic associated fatty liver disease and metabolic associated steatohepatitis: Challenges and opportunities.World journal of stem cells · 2025Review
- Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Recent advances in non-alcoholic steatohepatitis-associated hepatocellular carcinoma: immune cells, metabolic dysregulation, and therapeutic strategies.Frontiers in oncology · 2025Review
- Mini-review: Serum immunoglobulins and MASLD.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic liver diseases worldwide in recent decades. Metabolic diseases like excessive blood glucose, central obesity, dyslipidemia, hypertension, and liver function abnormalities cause NAFLD. NAFLD significantly increases the likelihood of liver cancer, heart disease, and mortality, making it a leading cause of liver transplants. Non-alcoholic steatohepatitis (NASH) is a more advanced form of the disease that causes scarring and inflammation of the liver over time and can ultimately result in cirrhosis and hepatocellular carcinoma. In this review, we briefly discuss NAFLD's pathogenic mechanisms, their progression into NASH and afterward to NASH-related cirrhosis. It also covers disease epidemiology, metabolic mechanisms, glucose and lipid metabolism in the liver, macrophage dysfunction, bile acid toxicity, and liver stellate cell stimulation. Additionally, we consider the contribution of intestinal microbiota, genetics, epigenetics, and ecological factors to fibrosis progression and hepatocellular carcinoma risk in NAFLD and NASH patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.